Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Accumulated Expenses (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Accumulated Expenses for 4 consecutive years, with $43000.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 99.94% to $43000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43000.0 through Dec 2025, down 99.94% year-over-year, with the annual reading at $43000.0 for FY2025, 99.94% down from the prior year.
  • Accumulated Expenses hit $43000.0 in Q4 2025 for Axsome Therapeutics, down from $12.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $74.0 million in Q4 2024 to a low of $43000.0 in Q4 2025.
  • Historically, Accumulated Expenses has averaged $14.3 million across 4 years, with a median of $6.6 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 1147.71% in 2024 and later plummeted 99.94% in 2025.
  • Year by year, Accumulated Expenses stood at $1.6 million in 2022, then skyrocketed by 266.54% to $5.9 million in 2023, then surged by 1147.71% to $74.0 million in 2024, then tumbled by 99.94% to $43000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for AXSM at $43000.0 in Q4 2025, $12.7 million in Q3 2025, and $46000.0 in Q2 2025.